Login to Your Account



Another Attempt at Glucokinase

Blocking Interaction Allows More Specific Targeting

By Anette Breindl
Science Editor

Friday, November 15, 2013
By disrupting the interaction between glucokinase and its regulatory protein, scientists at Amgen Inc. have managed to specifically affect high blood sugar levels in mouse models of diabetes, while having no effect on animals with normal blood sugar. Glucokinase has multiple roles in the control of blood sugar and “has been a compelling target for a number of years” for the treatment of Type II diabetes, senior author Clarence Hale told BioWorld Today. Thousand Oaks, Calif.-based Amgen has been among the companies pursuing that target.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription